Search | Clinical Trials Finder

Conditions: Type 1 Diabetes, Diabetic Kidney Disease, Cardiovascular Diseases, Endothelial Dysfunction, Insulin Sensitivity
Interventions: Metformin Hcl 1000Mg Tab, Aminohippurate Sodium 20 % Injection, Iohexol 300 Mg/mL Injectable Solution, Placebo; Drug
Lead sponsor: Kalie Tommerdahl; Other
Eligibility: 12 Years to 25 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 2
States / cities: Aurora, Colorado • Seattle, Washington

Conditions: Diabetes Mellitus, Insulin-Dependent
Interventions: The GlucoWatch® G2™ Biographer (GW2B), The Continuous Glucose Monitoring System (CGMS™); Device
Lead sponsor: Jaeb Center for Health Research; Other
Eligibility: 1 Year to 17 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002
U.S. locations: 6
States / cities: Stanford, California • Denver, Colorado • New Haven, Connecticut + 3 more

Conditions: Type 1 Diabetes Mellitus
Interventions: CGM and Insulin Pump, Closed-Loop Control System; Device
Lead sponsor: Sansum Diabetes Research Institute; Other
Eligibility: 21 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 3
States / cities: Santa Barbara, California • Rochester, Minnesota • Charlottesville, Virginia

Conditions: Gestational Diabetes, Hyperglycemia
Interventions: Continuous glucose monitor, Oral Glucose Tolerance Test, Hemoglobin A1c; Device · Diagnostic Test
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes Mellitus
Interventions: Oral Anti-diabetes Drugs alone, Basal bolus insulin, Supplemental insulin, Continuous glucose monitoring (CGM); Drug · Device
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 85 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Type 2 Diabetes
Interventions: Continuous Glucose Monitor and Undermyfork App, Continuous Glucose Monitor; Other
Lead sponsor: Scripps Whittier Diabetes Institute; Other
Eligibility: 18 Years to 80 Years
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Endometrial Cancer
Interventions: Prolonged Overnight Fasting (POF), Blood Specimen Collection, Blood Sugar Monitor, Hysterectomy; Behavioral · Procedure · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: PreDiabetes, Type 2 Diabetes, Healthy
Interventions: Time Restrictive Eating- late, Time Restrictive Eating- early, Time Restrictive Eating- early with early caloric intake, Macronutrient-controlled meals; Behavioral · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type1 Diabetes Mellitus
Interventions: iLet Bionic Pancreas insulin-only configuration with Humalog or Novolog, iLet Bionic Pancreas insulin-only configuration with Fiasp, Usual care; Device · Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 3
States / cities: Palo Alto, California • Aurora, Colorado • Jacksonville, Florida

Conditions: Diabetes Mellitus Type 1
Interventions: iPhone bionic pancreas, iLet bionic pancreas, Xeris Xerisol glucagon, Lilly glucagon, iLet infusion set, Contact Detach infusion set; Device · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes Mellitus
Interventions: t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, t:slim X2 with Basal-IQ & Dexcom G6 CGM; Device
Lead sponsor: University of Virginia; Other
Eligibility: 14 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 7
States / cities: Santa Barbara, California • Stanford, California • Aurora, Colorado + 4 more

Conditions: Diabetes Mellitus, Hyperglycemia, Hypoglycemia
Interventions: Continuous glucose Monitoring Devices and Clarity Software, Point of Care (POC) blood glucose; Device · Other
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Diabetes Mellitus
Interventions: GBP CGM; Device
Lead sponsor: University of Virginia; Other
Eligibility: 21 Years to 65 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Type2 Diabetes
Interventions: Continuous Glucose Monitor (CGM), Activity Tracker, Coaching; Device · Behavioral
Lead sponsor: Savvysherpa, Inc.; Industry
Eligibility: 65 Years and older
Enrollment: 358 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: Diabetes
Interventions: Continuous Glucose Monitoring and Education Support; Other
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Surgery--Complications
Interventions: Dexcom G6 continuous glucose monitor; Device
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Type 1 Diabetes
Interventions: Automated Insulin Delivery Adaptive NETwork (AIDANET), AIDANET+ BPS_RL→AIDANET; Device
Lead sponsor: Sue Brown; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes Mellitus (DM)
Interventions: Dexcom G6; Device
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years to 50 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: PreDiabetes
Interventions: Real time continuous glucose monitor (Stelo); Device
Lead sponsor: Young Men's Christian Association of the Blue Water Area; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Port Huron, Michigan

Conditions: Type 1 Diabetes
Interventions: Predictive Low Glucose Minimizer; Device
Lead sponsor: Animas Corporation; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Diabetes Mellitus, Type 2
Interventions: CGM, SMBG; Device
Lead sponsor: DexCom, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Huntington Beach, California • Temecula, California • Atlanta, Georgia + 5 more

Conditions: Gestational Diabetes Mellitus as Antepartum Condition
Interventions: myo-inositol, Continuous glucose monitoring surveillance, Glucose monitoring; Dietary Supplement · Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 13 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Glucose Metabolism
Interventions: Predefined meal; Combination Product
Lead sponsor: Texas A&M University; Other
Eligibility: 60 Years to 85 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: College Station, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Effect of Physical Activity on Type II Diabetes Mellitus; Behavioral
Lead sponsor: National Institute of Nursing Research (NINR); NIH
Eligibility: 19 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2005
U.S. locations: 2
States / cities: Pittsfield, Massachusetts • Springfield, Massachusetts

Search by objective public record fields.

MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes

Continuous Glucose Monitors for Children With Diabetes Mellitus

At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation

Early Investigation of Glucose Monitoring After Gestational Diabetes Pilot

Oral Anti Diabetic Agents in the Hospital

Pilot RCT Evaluating Clinical Outcomes of Using Undermyfork Mobile App With Dexcom G7

Fasting InTervention for Endometrial Cancer

Effect of Meal Composition and Timing Modification on Glucose Metabolism, Body Temperature and Sleep

The Insulin-Only Bionic Pancreas Bridging Study

The iLet Introduction Study: A Feasibility Study of the iLet, a Fully Integrated Bihormonal Bionic Pancreas

The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas (DCLP3 Extension)

CGM/Clarity Use, Glycemic Control and Clinical Outcomes

A Clinical Study of the Performance of a Glucose Blinding Protein-Based Continuous Glucose Monitor (GBP CGM)

Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics - (Protocol 3)

Continuous Glucose Monitoring and Diabetes

Accuracy of the Dexcom G6 Continuous Glucose Monitoring System Following Cardiac Surgery

Safety and Feasibility of a Machine-Learning Bolus Priming Added to Existing Control Algorithm

Continuous Glucose Monitoring for Personal Protective Equipment Evaluation

The YMCA Healthy Lifestyle Program for Prediabetes

Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia

Continuous Glucose Monitoring & Management In Type 2 Diabetes (T2D)

Glycemic Impact of Myo-inositol in Pregnancy

Macronutrient Distribution and Plasma Metabolites to Model Meals Composition

Changing Physical Activity Behavior in Individuals With Type 2 Diabetes Using Counceling and Information From Continuous Glucose Monitoring